Difference between revisions of "Rivaroxaban (Xarelto)"
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 21: | Line 21: | ||
*11/4/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm FDA approved] to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ''(Non-hematologic indication)'' | *11/4/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm FDA approved] to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ''(Non-hematologic indication)'' | ||
*11/2/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm FDA approved] for the treatment of [[Venous thromboembolism|deep vein thrombosis (DVT), pulmonary embolism (PE)]], and for the reduction in the risk of recurrence of DVT and of PE. | *11/2/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm FDA approved] for the treatment of [[Venous thromboembolism|deep vein thrombosis (DVT), pulmonary embolism (PE)]], and for the reduction in the risk of recurrence of DVT and of PE. | ||
| − | + | ==History of changes in EMA indication== | |
| + | *9/30/2008: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BAY 59-7939 | *'''Code name:''' BAY 59-7939 | ||
| Line 37: | Line 38: | ||
[[Category:Venous thromboembolism medications]] | [[Category:Venous thromboembolism medications]] | ||
| + | [[Category:EMA approved in 2008]] | ||
[[Category:FDA approved in 2011]] | [[Category:FDA approved in 2011]] | ||
Revision as of 12:19, 31 December 2022
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Reversal information
Factor Xa, recombinant, inactivated-zhzo (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.
Diseases for which it is used
- Atrial fibrillation
- Venous thromboembolism
Patient drug information
- Rivaroxaban (Xarelto) package insert[1]
- Rivaroxaban (Xarelto) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/1/2011: FDA approved for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.
- 11/4/2011: FDA approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (Non-hematologic indication)
- 11/2/2012: FDA approved for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE.
History of changes in EMA indication
- 9/30/2008: Initial authorization
Also known as
- Code name: BAY 59-7939
- Brand name: Xarelto